Attached files

file filename
EX-99.1 - EX-99.1 - Oncternal Therapeutics, Inc.a14-4504_1ex99d1.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported) January 29, 2014

 

GTx, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

000-50549

 

62-1715807

(State or Other Jurisdiction

of Incorporation)

 

(Commission File
Number)

 

(IRS Employer Identification No.)

 

175 Toyota Plaza

7th Floor

Memphis, Tennessee

 

38103

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (901) 523-9700

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

ITEM 8.01            Other Events.

 

On January 29, 2014, GTx, Inc. (the “Company”) issued a press release announcing that preliminary findings from the Company’s Phase 2 clinical trial evaluating GTx-758 (Capesaris®), an oral estrogen receptor alpha agonist, in men with metastatic castrate resistant prostate cancer will be presented on Thursday, January 30, 2014, during the 2014 American Society of Clinical Oncology Genitourinary Cancer Symposium being held in San Francisco, California.

 

A copy of the press release is furnished as Exhibit 99.1 to this Current Report.

 

ITEM 9.01            Financial Statements and Exhibits.

 

(d)           Exhibits.

 

Exhibit
Number

 

Description

99.1

 

Press Release issued by GTx, Inc. dated January 29, 2014

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: January 29, 2014

GTx, Inc.

 

 

 

 

 

By:

/s/ Henry P. Doggrell

 

Name:

Henry P. Doggrell

 

Title:

Vice President, Chief Legal Officer and Secretary

 

3